Metagenomi Therapeutics, Inc. Cash Flow Statement
MGX|2 years of annual SEC 10-K data (FY2024-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
Metagenomi Therapeutics, Inc. used $89M in operating cash flow and negative free cash flow of $89M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.90 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Net Income | -$87.9M | -$68.3M |
| Depreciation & Amortization | - | $4.2M |
| Operating Cash Flow | -$88.9M | -$91.4M |
| Capital Expenditures | $574.0K | $9.8M |
| Free Cash Flow | -$89.5M | -$101.2M |
| FCF Margin | -354.9% | -226.2% |